CCM vs MLAB vs RDNT vs NEOG

For growth investors, RadNet, Inc.

(RDNT) is the stronger pick with 11. 5% revenue growth year-over-year, versus -28. 6% for Concord Medical Services Holdings Limited (CCM). Analysts rate Concord Medical Services Holdings Limited (CCM) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, RadNet, Inc.

(RDNT) delivered a total return of +147. 1%, compared to -84. 9% for Concord Medical Services Holdings Limited (CCM). Over 10 years, the gap is even starker: RDNT returned +961. 2% versus CCM's -87. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Concord Medical Services Holdings Limited (CCM) is the lower-risk stock at 0.

51β versus Mesa Laboratories, Inc. 's 1. 75β — meaning MLAB is approximately 246% more volatile than CCM relative to the S&P 500. On balance sheet safety, Neogen Corporation (NEOG) carries a lower debt/equity ratio of 44% versus 2% for Concord Medical Services Holdings Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), RadNet, Inc.

(RDNT) is pulling ahead at 11. 5% versus -28. 6% for Concord Medical Services Holdings Limited (CCM). On earnings-per-share growth, the picture is similar: Mesa Laboratories, Inc. grew EPS 99. 2% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

RadNet, Inc.

(RDNT) is the more profitable company, earning 2. 3% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 2. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLAB leads at 6. 8% versus -138. 6% for CCM. At the gross margin level — before operating expenses — MLAB leads at 62. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Concord Medical Services Holdings Limited (CCM) trades at 1.

4x forward P/E versus 94. 4x for RadNet, Inc. — 93. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RDNT: 60. 0% to $92. 00.

In this comparison, MLAB (0.

6% yield) pays a dividend. CCM, RDNT, NEOG do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Concord Medical Services Holdings Limited (CCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51)). Neogen Corporation (NEOG) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCM: -87. 5%, NEOG: -50. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CCM (Healthcare) and MLAB (Technology) and RDNT (Healthcare) and NEOG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

MLAB pays a dividend while CCM, RDNT, NEOG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.